Apr 24, 2020
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Oct 29, 2019
Aggressive Screening Urged To Detect Rare Lung Complication Among Children With Severe Form Of Arthritis
Jun 06, 2019
JOMS Study: New Treatment Protocol Created for Children with Arthritis Affecting the Jaw Joints
May 29, 2019
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
May 02, 2019
Mallinckrodt to Present Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019)
Apr 29, 2019
The ACR and the Arthritis Foundation Present New Guidelines Offering Therapeutic Approaches and Treatment Options for Juvenile Idiopathic Arthritis
Apr 09, 2019
Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics
Mar 21, 2019
Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
Feb 05, 2019
Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA)
Feb 04, 2019
Enzyvant to Highlight Investigational RVT-801 Program and Farber Disease Natural History Study at Upcoming WORLDSymposium(TM)
Oct 26, 2018
First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Jun 28, 2018
Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Jun 18, 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar® Gel (Repository Corticotropin Injection) Studies
Feb 05, 2018
Quebec adds Erelzi(TM) (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
Nov 16, 2017
British Columbia and Prince Edward Island become the first provinces to add Erelzi(TM) (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
Jul 21, 2017
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis